OncoSil Managing Director and CEO Nigel Lange said:

"These independent findings represent an important step in our formulation development program. The rheology data support continued investigation of higher-concentration formulations and provide a strong rationale for the next phase of testing, which will evaluate injectability. We're encouraged by these results and look forward to building on them as the program advances."